I&I to Reorg in May for Summer Deployment

Looks like Angela Wong made the decision to pull a reorg committee together to outline a realignment with Xeljanz division within I&I by the Summer.

She & Micheal Gladstone who just camr over, questions the recent GI expansion & all the 2 rep as well as triad territories given the probability of severe FDA Xeljanz label restrictions including being removed out of GI.

Before the stupid crazy GI expansion a couple yrs ago, Xeljanz had 125 reps & 10 DMs calling on Rhuems.
(Now we have 300 reps & 28 DMs)

So these factual numbers should give you an idea of the upcoming downsizing back to calling on just Rhuems with last line restricted Xeljanz RA label.

 

Surprise they dont just collapse the division with patent LOE in 2024!

Good odds FDA might pull the drug entirely from the market given recent news as FDA is not happy w Pfizer VP Pres & senior leaders hiding these CV events for 5yrs & flat out lying or downplaying to employees & physicians about it

 

The FDA already has restrictions on the use of Pfizer’s JAK inhibitor Xeljanz at a higher dose because of safety concerns. Now, thanks to new red flags, the agency is weighing a move to tighten those restrictions.

In a post Thursday, the=>=> FDA alerted patients and doctors that a postmarket study has linked Xeljanz to an increased risk of serious heart-related problems and cancer compared with TNF inhibitors, a group that includes such drugs as AbbVie’s Humira. The **=>>problems applied to both the 5-mg twice-daily dose and the higher 10-mg strength.

The agency said it’ll evaluate the clinical trial results and consider what moves to take. The **last time it made that kind of comment, it wound up putting a boxed warning on the high dose and stripping it of its use in previously untreated ulcerative colitis.

 

The FDA already has restrictions on the use of Pfizer’s JAK inhibitor Xeljanz at a higher dose because of safety concerns. Now, thanks to new red flags, the agency is weighing a move to tighten those restrictions.

In a post Thursday, the=>=> FDA alerted patients and doctors that a postmarket study has linked Xeljanz to an increased risk of serious heart-related problems and cancer compared with TNF inhibitors, a group that includes such drugs as AbbVie’s Humira. The **=>>problems applied to both the 5-mg twice-daily dose and the higher 10-mg strength.

The agency said it’ll evaluate the clinical trial results and consider what moves to take. The **last time it made that kind of comment, it wound up putting a boxed warning on the high dose and stripping it of its use in previously untreated ulcerative colitis.

Going to be FDA bloodbath

 

Hate to say it for the couple hundred reps hired for GI, but a downsizing realignment is much needed & overdo and cant happen fast enough.

I and most my district in the East Region have counterparts & it is a total disaster stepping on each other. We have these crazy call goals that forces us to do calls together & pre covid joint calls and luncheons just to check the box with calls.
We just laugh about having 300-400k of salaries on calls together basically sample dumping & feeding people. All reps across nation doing the same thing as we all talk but we dont say anything to management as we dont want to eliminate our jobs.
I m good friends w my DM and she says the DMs across nation feel same way that they have too many reps & should have 12 DMs not 28 but they also dont want to talk self out of job.....

But their are not enough offices for 2 reps to call on for a 2wk rotation so we go together alot. Even virtually on calls together so we both record a call on same office to "double count" calls to meet these crazy call goals.

We only have a few years left w Xeljanz and now will be very restricted in use probably for people under 50 with no high blood pressure or CV plus likely to require blood test monitoring quarterly & annual EKG/Echo.
It is going to be more challenges with 2 reps so a 50% downsizing is much needed unfortunately.

 

And now in some GI offices there are 3 reps. Brilliant strategy. If the Dr wasn’t seeing 2, why would they suddenly see this 3rd one?

 

we were doomed at the start when we put together the yes-bots that Jay wanted
Miles did his best and pulled off a miracle with the 2nd string RSDs he inherited
the facade came down when he bolted

put a fork in this drug

 

First thing they should do is put a hiring freeze on. If they had done that last year, they would be practically right-sized with all the turnover.

 

The most bonehead unintelligent thing our VP has done. He has a marketing robot stuck in 1990s with more reps = more sales, doesnt matter what side effects are.
This is what happens when you promote a non-leader of people to run a salesforce with zero experience (never was a rep or DM or RD--- zippo in sales)
He should be terminated for not being qualified or having the skill sets but also just for this stupid A.. decision w GI

 

Very true. With all the turnover in 2020 attrition would have right size Xeljanz going into last years of patent LOE let alone the hidden CV issues that have come out.
But again that is what a smart strategic leader would do---- we dont have that thus we are in the position we are in facing a 50% gutting of the division.

 

They must know something about the data then if they are assuming strict FDA restrictions.

 

It’s all about empire building. Isn’t it funny that actually they use the sales to justify hiring more reps when the sales were already there... it’s ass backward thinking, But it’s happened before and it’ll happen again. People just love to build empires.

 

And the answer to these stupid a s decisions to expand couple years ago & most recently this Dec , you have to look no further than the Pres & VP.... if you know them then enough said.

 

LMFAO
They have known about this if not since luaunch 8yrs ago then at least 5yrs when Marketing VP (Sales VP now) stood on stage at National Meeting in front of us reps saying there are some "rumors" and "unfounded" CV events going around ACR, and he just wanted to assure the reps that there is no risks and to keep on selling his marketing message & strategy to meet the Billion dollar goal and his 10million DTC buyout he pressured HQ for.

They knew but it was all about sales sales sales and making billion dollar goal so he could get his 250k a year stock options which he has millions.
Sad Sad Sad

 

This will happen but has been put on hold pending the FDA revising Xeljanz label.
Likely changes in the Late Summer/Fall.

 

Heard same from HQ friend that Q3-Q4 is the blood bath X date!

 

Xeljanz and it's group has a 2 year guarantee after the 26 GSRs were added. Nothing well happen in 2021 or 2022. Fair game after that. Your HQ friend must be a janitor with that quality of information you shared.

 

Lets sell Xeljanz to patients as a first line therapy despite the risk of pulmonary embolism! Lol

 

Why would they wait because of this?